Current Status of Oseltamivir Application and Its Future Development Trend
DOI:
https://doi.org/10.62051/8tw69b97Keywords:
Oseltamivir; adverse effect; mechanism.Abstract
Influenza is a common respiratory disease with severe complications that can be fatal in severe cases. Oseltamivir is a drug that suppresses influenza disease, it can effectively reduce the symptoms of influenza patients but there are also some adverse effects that can affect the quality of life of patients and the psychological status of the treatment process. This article examines the side effects, mechanism of action, trends, and future prospects of oseltamivir, and draws conclusions about the drug's use in treating influenza. It provides direction and reference information for future research on this drug, discusses the limitations of its therapeutic efficacy and the challenges it will face. Liver enzyme levels should be carefully monitored and liver health should be carefully assessed when using oseltamivir to treat illnesses such as influenza. These studies will help provide better options for the treatment of diseases such as influenza. However, this paper has not addressed the limitations of whether oseltamivir has additional adverse effects in patients with hepatic and renal disorders, whether they can take the drug normally, and whether the dosage needs to be reduced compared to normal patients. In addition, even though oseltamivir is very effective against the influenza virus, it is not a perfect solution to all problems. It still has limitations and challenges to overcome in terms of viral suppression. In future studies, a deeper understanding of the mechanism of action, efficacy and safety of oseltamivir is needed to develop better anti-influenza drugs to serve patients.
Downloads
References
[1] Davies BE. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Journal of Antimicrobial Chemotherapy, 2010, 65(suppl_2): ii5-ii10.
[2] Chen J, et al. Advances in Development and Application of Influenza Vaccines. Frontiers in Immunology, 2021, 12.
[3] Sur M, et al. Oseltamivir. PubMed, StatPearls Publishing, 2024. Available at: www.ncbi.nlm.nih.gov/books/NBK539909/.
[4] Li XG, et al. Oseltamivir Treatment for Influenza during the Flu Season of 2018–2019: A Longitudinal Study. Frontiers in Microbiology, 2022, 13.
[5] Dobson J, et al. Oseltamivir Treatment for Influenza in Adults: A Meta-Analysis of Randomised Controlled Trials. The Lancet, 2015, 385(9979): 1729–1737.
[6] Kumar S, et al. Oseltamivir Analogs with Potent Anti-Influenza Virus Activity. Drug Discovery Today, 2020, 25(8): 1389–1402.
[7] Enkirch T, et al. Identification and in vivo efficacy assessment of approved orally bioavailable human host protein-targeting drugs with broad anti-influenza A activity. Frontiers in Immunology, 2019, 10: 1097.
[8] Gagnon A, et al. Pandemic paradox: early life H2N2 pandemic influenza infection enhanced susceptibility to death during the 2009 H1N1 pandemic. mBio, 2018, 9(1): e02091–e02017.
[9] Lampejo T. Influenza and Antiviral Resistance: An Overview. European Journal of Clinical Microbiology & Infectious Diseases, 2020, 39(7): 1201–1208.
[10] Lew W, et al. Discovery and development of GS 4104 (oseltamivir), an orally active influenza neuraminidase inhibitor. Journal, 2000, 7(6): 663–672.
[11] Świerczyńska M, et al. Antiviral Drugs in Influenza. International Journal of Environmental Research and Public Health, 2022, 19(5): 3018.
[12] Ventura S, et al. Oseltamivir-Induced Upper Gastrointestinal Bleeding. Journal of Gastrointestinal and Liver Diseases, 2023, 32(3): 412–413.
[13] Dai Z, et al. Early Administration of Oseltamivir within 48 Hours after Onset of Flulike Symptoms Can Reduce the Risk of Influenza B Virus-Associated Pneumonia in Hospitalized Pediatric Patients with Influenza B Virus Infection. The Pediatric Infectious Disease Journal, 2020, 39(2): e20–e22.
[14] Davies BE. Pharmacokinetics of oseltamivir: An oral antiviral for the treatment and prophylaxis of influenza in diverse populations. Journal of Antimicrobial Chemotherapy, 2010, 65(Supplement 2): ii5–ii10.
[15] Leung C, et al. Effectiveness of Oseltamivir in Reducing COVID-19 Related In-Hospital Deaths: A Pharmacoepidemiologic Study. International Journal of Antimicrobial Agents, 2024.
[16] Drugs.com. Oseltamivir Prices, Coupons, Copay Cards & Patient Assistance. 2024. Available at: www.drugs.com/price-guide/oseltamivir#:~:text=The%20cost%20for%20oseltamivir%2075%20mg%20oral%20capsule.
Downloads
Published
Conference Proceedings Volume
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.